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High systemic drug toxicity and increasing prevalence of drug
resistance hampers efficient treatment of human African
trypanosomiasis (HAT). Hence, development of new highly
specific trypanocidal drugs is necessary. Normal human serum
(NHS) contains apolipoprotein L-I (apoL-I), which lyses African
trypanosomes except resistant forms such as Trypanosoma
brucei rhodesiense1. T. b. rhodesiense expresses the apoL-I–
neutralizing serum resistance–associated (SRA) protein2,
endowing this parasite with the ability to infect humans and
cause HAT. A truncated apoL-I (Tr-apoL-I) has been engineered
by deleting its SRA-interacting domain, which makes it lytic for
T. b. rhodesiense1. Here, we conjugated Tr-apoL-I with a single-
domain antibody (nanobody) that efficiently targets conserved
cryptic epitopes of the variant surface glycoprotein (VSG)
of trypanosomes3 to generate a new manmade type of
immunotoxin with potential for trypanosomiasis therapy.
Treatment with this engineered conjugate resulted in
clear curative and alleviating effects on acute and chronic
infections of mice with both NHS-resistant and NHS-
sensitive trypanosomes.
T. b. rhodesiense is the causative agent of HAT in eastern Africa4,5. In
endemic foci, large-scale infections of livestock represent a continuous
threat for epidemic outbreaks5–7. Trypanosomes evade host immune
responses by continuously changing the VSGs that cover their entire
membrane, which leaves little prospect for a conventional vaccine8,9.
Thus, the treatment of sleeping sickness relies on therapy. The disease
is fatal if left untreated, and the two drugs currently available, suramin
and melarsoprol10, can cause serious adverse events resulting from
drug toxicity, relapses, long duration of treatment and increasing drug
resistance11–13. Therefore, development of new drugs is necessary.
NHS is able to lyse African trypanosomes, except those that
cause HAT14. Recently, a human-specific serum protein, apoL-I, was
identified as the trypanolytic factor of NHS1. When isolated from
livestock, T. b. rhodesiense is sensitive to lysis by NHS6. But this
parasite becomes resistant to NHS after expression of the SRA
protein2,15,16. SRA inhibits the trypanolytic activity of apoL-I by
interacting with its C-terminal domain1. Deleting the SRA-interacting
domain of apoL-I results in Tr-apoL-I, which cannot be neutralized by
SRA and thus is capable of lysing both NHS-sensitive and NHS-
resistant T. b. rhodesiense1.
Tr-apoL-I represents a natural trypanolytic agent to cure T. b.
rhodesiense infections. But competition with endogenous apoL-I
(10 mg/ml in NHS)17,18, whose association with carrier high-density
lipoprotein (HDL) particles allows fast uptake by the parasite14, might
interfere with its delivery to trypanosomes. Therefore, targeting Tr-
apoL-I to the parasite surface is required to improve its efficiency.
Nanobodies, the single-domain antigen-binding fragments derived
from camel heavy-chain antibodies, represent exquisite targeting
tools because of their small size (13 kDa) and strict monomeric
behavior19–21. We identified a nanobody that binds to various VSGs
(NbAn33)3. NbAn33 specifically recognizes oligomannose, as indi-
cated by its binding to synthetic Man9 and Man7 but not Man3, and by
the strong reduction of binding to the AnTat 1.1 VSG treated with
alpha-mannosidase (Fig. 1a). Accordingly, NbAn33 binds equally well
to the MiTat 1.4, MiTat 1.2 and MiTat 1.5 VSGs that represent the
three different VSG classes (I, II and III, respectively) and share the
conserved N-linked Man5–9 carbohydrate
22 (Fig. 1a). NbAn33 also
binds to the ETat 1.2 VSG expressed in NHS-resistant T. b. rhodesiense.
Therefore, we used NbAn33 to generate a general VSG-recognizing
nanobody–apoL-I construct.
Figure 1b summarizes the design of nanobody–apoL-I constructs
tested here. apoL-I contains an N-terminal signal peptide (amino acids
1–27), a C-terminal SRA-interacting domain (amino acids 343–398)
and a central lytic domain (amino acids 28–342)1,23. In Tr-apoL-I,
both signal peptide and C-terminal domain were deleted. A nano-
body-encoding region was added, spaced from Tr-apoL-I by a
sequence encoding the natural llama g2c antibody hinge, allowing
independent folding of the two protein subunits24. NbAn33–Tr-
apoL-I was able to specifically recognize trypanosomes and did not
bind at a detectable level to fixed blood cells or to non–fixed-cell
suspensions of liver, lymph nodes and spleen of infected mice (Fig. 1c).
NbAn33–Tr-apoL-I exhibited a dose-dependent trypanolytic activ-
ity with a dose of 10 mg/ml (180 nM), lysing 100% of the parasites
(that is, 106; stumpy and slender forms) within 4 h of incubation
(Fig. 2a). Under these conditions, replacement of NbAn33–Tr-apoL-I
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with a 20-fold molar excess of NbAn33 showed no lytic activity,
whereas 50% NHS (approximately 4 mg/ml apoL-I) lysed 70% of the
parasites. To evaluate the contribution of the targeting module to
trypanolysis, we substituted NbAn33 with NbCEA5 (ref. 24), a nano-
body recognizing an irrelevant antigen. No trypanolysis was observed
with 10 mg NbCEA5–Tr-apoL-I/ml (Fig. 2b), showing the crucial role
of NbAn33. Accordingly, the lytic activity of NbAn33–Tr-apoL-I was
completely inhibited after preincubation with soluble VSG (Fig. 2b).
NbAn33–Tr-apoL-I was also highly trypanolytic for NHS-resistant
T. b. rhodesiense ETat 1.2R (Fig. 2b). This required truncation of the
SRA-interacting domain, because the full nanobody–apoL-I conjugate
(NbAn33–apoL-I) was only lytic for ETat 1.2S (Fig. 2b). In accordance
with the oligomannose specificity of NbAn33, all trypanosome
variants used for the nanobody-VSG binding assay were lysed
by NbAn33–Tr-apoL-I but not by NbCEA5–Tr-apoL-I (Fig. 2c).
Thus, NbAn33–Tr-apoL-I efficiently lysed both NHS-sensitive and
NHS-resistant trypanosomes in vitro.
We tested the performance of NbAn33–Tr-apoL-I in mouse models
of HAT. Upon detection of virulent NHS-resistant, and as such
potentially human pathogenic, T. b. rhodesiense ETat 1.2R parasites
in blood (day 3), we treated mice with a single intraperitoneal
inoculation of 10–100 mg NbAn33–Tr-apoL-I or NbCEA5–Tr-apoL-I
per mouse. Treatment with a single dose of 20 mg NbAn33–Tr-apoL-I
(Fig. 3a,b) or higher (data not shown) resulted in complete parasite
clearance, no obvious adverse symptoms for mice and long-term
survival (60 d when experiments were terminated). Mice treated with
a suboptimal dose of 10 mg/mouse were partially protected, as
evidenced by a delayed parasitemia and longer median survival
(9 d) as compared to control NHS-treated mice (6 d). The intravenous
injection of 5 mg conjugate achieved the same effects as 20 mg injected
intraperitoneally. Only marginal protection was obtained after intra-
peritoneal injection of a high dose (100 mg/mouse) of nontargeting
NbCEA5–Tr-apoL-I (Fig. 3a,b) or recombinant apoL-I, and approxi-
mately 1 mg/mouse of apoL-I was required to abrogate parasitemia
(data not shown).
The NbAn33–Tr-apoL-I treatment was also assessed in a more
chronic T. b. brucei pleomorphic AnTat 1.1 infection. Here, para-
sitemia was cleared completely with a single dose of 20 mg NbAn33–
Tr-apoL-I injected intraperitoneally (Fig. 3c)
and mice survived until the experiment was
terminated (150 d, Fig. 3d). Mice treated with
a subcurative dose of 10 mg showed reduced
first peak of parasitemia and prolonged sur-
vival, but succumbed to late-stage parasitemia
(median survival of 61 d). Control mice,
treated with phosphate-buffered saline (PBS)
or 100 mg nontargeting NbCEA5–Tr-apoL-I,
died from parasitemia with a median survival
of 30 and 36 d, respectively.
Finally, we evaluated the NbAn33–Tr-apoL-I
treatment during the chronic phase of infection. Just before the onset of
the second wave of parasitemia with T. b. brucei AnTat 1.1 (day 12), we
injected mice intraperitoneally twice (2-d interval between injections)
with 20 mg NbAn33–Tr-apoL-I. Parasites were promptly cleared and
treated mice remained free of parasite for 50 d (Fig. 4a). Between
days 55 and 65 of infection, however, parasites reappeared in the
blood, and mice succumbed to infection with a median survival
of 70 d (Fig. 4b). Mice treated with 20 mg nontargeted NbCEA5–
Tr-apoL-I showed unaltered parasitemia and similar median survival
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Figure 2 In vitro trypanolysis. (a) Concentration-dependent lytic activity
on T. b. brucei AnTat 1.1 after a 4-h incubation (dotted lines, lysis by
50% NHS or 20-fold molar excess of NbAn33). (b) Trypanolytic activity
of different chimeras (10 mg/ml) on 106 T. b. brucei AnTat 1.1 and
T. b. rhodesiense ETat 1.2S (S) and ETat 1.2R (R; 4-h incubation).
(c) Trypanolytic activity of NbAn33–Tr-apoL-I and a nontargeted control
chimera (10 mg/ml, 4-h incubation) on trypanosomes expressing unrelated
VSGs that share the conserved Man5–9 carbohydrate
22.
Figure 1 Targeting modules for the trypanosome
surface. (a) Targeting specificity of NbAn33, as
determined by ELISA using NbAn33. (b) Con-
structs used in this study. Chimeras contain a six-
histidine (His6) tag at the carboxy terminal for
purification purposes. (c) Staining of T. b. brucei
AnTat 1.1 in blood smears or various cell sus-
pensions from an infected mouse. The samples
were incubated with Alexa 488–labeled NbAn33–
Tr-apoL-I and illuminated with visible (Phase) or
ultraviolet (Alexa) light. LNC, lymph nodes.
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time (30 d) as PBS-treated mice. To trace the origin of the re-emerging
infection in the NbAn33–Tr-apoL-I–treated mice, the post-treatment
presence of mRNA encoding VSGs was checked in lungs, liver, spleen,
lymph nodes, peritoneal exudate cells (PECs), thymus, kidney, eyes,
ovaries and brain. VSG-encoding RNA was detected only in liver
samples taken 4 weeks after treatment (Fig. 4c), indicating that
parasites might first re-emerge in the liver.
During chronic trypanosome infection, systemic inflammation is
associated with anemia, severe weight loss, splenomegaly, reduced
locomotor activity and increased level of serum aspartate transaminase
(AST)25–28. Treatment with 20 mg NbAn33–Tr-apoL-I at the onset of
the second peak of parasitemia rescued infection-associated anemia,
and the level of red blood cells remained normal until parasites
reappeared (Fig. 4d). This treatment also abolished other infection-
associated pathological features (Fig. 4e). Hence, even though a
treatment of 20 mg/mouse was insufficient to completely cure a
chronic infection, it was beneficial in alleviating several infection-
associated pathologies.
Administering NbAn33–Tr-apoL-I (20 mg/mouse) when parasites
reappeared in the bloodstream (day 60) of mice already treated at the
onset of the second parasitemia wave had no effect on parasitemia or
mice survival. The parasites from the final parasitemia had undergone
antigenic variation, as they were not expressing the original AnTat 1.1
VSG (Supplementary Fig. 1 online). Although variants lacking the
high-mannose NbAn33 target exist22, it is unlikely that in this case
parasites switched to such VSG expression, as trypanosomes purified
from treated or infected mice were found to be equally susceptible
to lysis by NbAn33–Tr-apoL-I in vitro and in vivo (Supplementary
Fig. 1). Induction of the host humoral response is more likely to be
responsible, as sera from mice treated twice with the chimera (50 mg/
mouse intraperitoneally on alternate days and boosted after 10 d)
reacted strongly with apoL-I (ELISA signal, OD405 4 0.65 at 1:500
dilution) and neutralized its activity. These sera did not react with
NbAn33, confirming its low immunogenicity in mice29. An even lower
immunogenicity is expected in humans, given the higher sequence
identity between nanobodies and human
variable immunoglobulin domains30. More-
over, as apoL-I is a human self-antigen, treat-
ment of humans with NbAn33–Tr-apoL-I
should not induce a humoral response against
this moiety.
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Figure 3 Therapeutic effects of NbAn33–Tr-apoL-I in acute infection.
(a,c) Parasitemia and (b,d) survival of mice infected with T. b. rhodesiense
ETat 1.2 R (a,b) or T. b. brucei AnTat 1.1 (c,d) and treated with 20 mg
(filled squares) or 10 mg (filled circles) NbAn33–Tr-apoL-I, or 100 mg
NbCEA5–Tr-apoL-I (open circles), with NHS (a,b; open squares) or PBS
(c,d; open squares) at 3 d after infection (arrow).
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Figure 4 Therapeutic effects of NbAn33–Tr-apoL-
I treatment at the second peak of parasitemia.
(a) Parasitemia and (b) survival of mice infected
with T. b. brucei AnTat 1.1. Treatment with
NbAn33–Tr-apoL-I (filled squares), NbCEA5–Tr-
apoL-I (open circles) or PBS (open squares).
(c) Detection of T. brucei VSG RNA in various
organs at different time points after treatment
with NbAn33–Tr-apoL-I (targeted treatment) or
NbCEA5–Tr-apoL-I (nontargeted treatment) at
the second peak of parasitemia. Results from
2 weeks and 1 week after treatment were
indistinguishable (data not shown). (d) Anemia
expressed as percent of red blood cells (RBCs) in
T. b. brucei–infected mice treated with NbAn33–
Tr-apoL-I (filled squares), NbCEA5–Tr-apoL-I
(open circles) or PBS (open squares) at days 12
and 14 after infection (arrows). (e) Pathological
features associated with trypanosome infection
in mice (25 d after infection). In each panel,
the black, gray and white bars represent values
for mice treated with NbAn33–Tr-apoL-I,
NbCEA5–Tr-apoL-I and PBS, respectively.
In all cases treatments were performed on
days 12 and 14 after infection (dotted line,
naive mice).
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In conclusion, we have developed a new trypanocidal modality
amenable to treatment of HAT, either alone or in combination with
less-curative doses of other trypanocidal drugs. Further developments
are possible, as substitution of NbAn33 with NbES31, a nanobody
directed against the ESAG6 subunit of the T. brucei transferrin
receptor, was equally potent in eliminating the parasite infection in
mice (T.N.B., K.C. & E.P., unpublished data). Finally, we anticipate
that this modality will be amenable to treatment of other infections,
depending on the availability of specific targeting nanobodies and a
host-derived natural defense molecule.
METHODS
Solid-phase binding ELISA. We coated 96-well plates with different VSGs
(1 mg/ml in 0.1 M NaHCO3, pH 8.2) overnight (4 1C), and performed ELISA as
previously described3. We removed mannose from AnTat1.1 VSG by incubating
100 mg VSG for 18 h at 25 1C with 10 units of alpha-mannosidase (Sigma)
followed by enzyme inactivation at 65 1C for 10 min and gel filtration. We
coated synthetic oligomannoses (Oxford Glycoscience) on peptide immobilizer
plates (Sanvertech), and then performed ELISA3.
Cloning and expression of nanobody–apoL-I. The truncated APOL1 gene was
amplified by PCR from a plasmid containing the APOL1 gene1 as NotI-XhoI
fragment with the following primer set (NotI-XhoI restriction sites are under-
lined): Apo42F, 5¢-ATAAGAATGCGGCCGCAGAGGAAGCTGGAGCGAGG
GT-3¢; Apo-TrR, 5¢-ATCCGCTCGAGGAAGCTTACAGGGGCCACAT-3¢. The
amplified truncated APOL1 fragment was cloned in NotI-XhoI–digested pET-
21d (+) (Novagen). The NbAn33–llama g2c hinge was amplified as BamHI-
NotI fragment with the following primer set (BamHI-NotI sites are underlined):
nanobody F, 5¢-ATCCGGGATCCCAGATGTGCAGCTGGTGGACTCT-3¢;
nanobody–MH-R, 5¢-ATAAGAATGCGGCCGCGGGAGCTTTGGGAGCTTTG
GAGCTGGGGTCTTCGCTGTGGTGCGCTGAGGAGACGGTGACCTGGGT-
3¢. The reverse primer includes the nucleotide sequence of the 15-mer llama g2c
hinge, coding for the amino acid sequence AHHSEDPSSKAPKAP. The ampli-
fied fragment was cloned in pET-21d (+) containing truncated APOL1. The
construct was transfected into BL21 Escherichia coli. The NbCEA5 conjugated
to truncated APOL1 was engineered likewise. As additional control, full APOL1
was amplified as NotI-XhoI fragment with the following primers set: Apo42F,
see above; ApoR, 5¢-ATCCGCTCGAGCAGTTCTTGGTCCGCCTGCA-3¢. All
recombinant proteins were expressed as cytosolic His-tagged products. After
lysis of the transformed BL21 cells, the recombinant fusion proteins were
purified using a Ni-NTA Superflow column (Qiagen). Further purification was
performed by gel filtration by high-performance liquid chromatography using a
Superdex 75 (10/30) column (Pharmacia, Akta Explorer 10S) equilibrated with
PBS. The proteins were checked in 10% SDS-PAGE.
Parasite binding of NbAn33–Tr-apoL-I. We labeled NbAn33–Tr-apoL-I with
Alexa 488 (Invitrogen). During parasitemia (T. b. brucei AnTat 1.1), we air-
dried thin blood smears and fixed them with methanol. After washing, we
flooded slides with Alexa-labeled NbAn33–Tr-apoL-I for 10 min and washed
them twice. We homogenized spleen, lymph nodes and liver of infected mice
and filtered cell suspensions through a cotton sieve. We incubated these cell
suspensions with Alexa-labeled NbAn33–Tr-apoL-I for 30 min and washed
them twice before mounting them on microscopic slides. The slides were
visualized with visible as well as ultraviolet light for immunofluoroscence
microscopy (Nikon ECLIPSE E600 with phase contrast).
In vitro trypanolysis assays. Parasites used for this assay included T. b. brucei
AnTat 1.1 (Institute of Tropical Medicine, Belgium), MiTat 1.1, MiTat 1.2,
Mitat 1.4 and MiTat1.5 (a gift from M.A.J. Ferguson, University of Dundee)
and T. b. rhodesiense ETat 1.2 S and ETat 1.2 R (Institute of Tropical Medicine,
Belgium). We expanded and purified parasites as previously described3. We
incubated purified parasites (106 parasites/ml phosphate saline-glucose buffer
with 5% FCS) with different chimeric proteins at 37 1C.
In vivo therapy experiments. Mouse care and experimental procedures were
performed under approval from the Ethical Committee of the Vrije Universiteit
Brussel. We intraperitoneally infected C57BL/6 mice with 5,000 parasites. Once
we detected parasites in blood by microscopy, mice received different doses
(from 10 to100 mg/mouse, four mice per group) of NbAn33–Tr-apoL-I.
Control mice were either left untreated or received NbCEA5–Tr-apoL-I or
NbAn33–apoL-I. After treatment, we followed parasitemia microscopically
every other day and recorded the survival of mice. To ensure the NHS resistance
of T. b. rhodesiense ETat 1.2 R, we infected mice with 500 ml NHS and
subsequently infected them with 5,000 parasites in 100 ml PBS. For the
treatment at the second peak of parasitemia, mice infected with T. b. brucei
(AnTat 1.1) were left untreated on the first peak of parasitemia. When we
detected the second wave of parasites microscopically, mice received intraper-
itoneal injections of NbAn33–Tr-apoL-I (20 mg/mouse), twice on alternate
days. Control mice were either left untreated or received NbCEA5–Tr-apoL-I.
We treated cohorts of four to five mice in parallel for each experimental setting
and repeated these experiments at least three times.
Detection of parasites by PCR. We prepared cell suspensions of various
organs at different time points after treatment on second peak of parasitemia.
We extracted total RNA from about 107 cells using the Trizol reagent
(Invitrogen). We used oligo(dT)12–18 primers (Gibco BRL) to synthesize
cDNA and performed PCR on mRNA encoding VSG with universal VSG
primers (mini-exon, 5¢-GCTATTATTAGAACAGTTTC-3¢; conserved 3¢-term-
inal 16-mer, 5¢-GTGTTAAAATATATCA-3¢) and checked the amplicon in 1.5%
agarose gel.
Assessment of pathological parameters. After treatment, we counted total red
blood cells every other day. We recorded the body weight, weight of spleen,
locomotor activity and serum AST levels of infected mice at 25 d after infection
for treated and untreated mice. We measured locomotor activity as the total
time spent per hour by mice on running in their cage, eating, drinking and
cleaning their fur and nest. The AST levels were measured from individual
mouse serum by a commercial kit (Boehringer Mannheim).
Accession codes. GenBank accession codes: Camelus dromedarius anti-VSG
immunoglobulin heavy chain variable domain cAbAn33 mRNA, AY263490;
llama g2c hinge, AX800153.
Note: Supplementary information is available on the Nature Medicine website.
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